Oxford Immunotec Global, which sells diagnostic tests for latent Tuberculosis infection, announced terms for its IPO on Friday. The Abingdon, United Kingdom-based company plans to raise $75 million by offering 5.4 million shares at a price range of $13 to $15. At the midpoint of the proposed range, Oxford Immunotec would command a fully diluted market value of $247 million.
Oxford Immunotec, which was founded in 2002 and booked $34 million in sales for the 12 months ended September 30, 2013, plans to list on the NASDAQ under the symbol OXFD. Oxford Immunotec Global initially filed confidentially on September 10, 2013. J.P. Morgan and Piper Jaffray are the joint bookrunners on the deal.
